What colorectal surgeons should know about probiotics: a review

Charlotte Kvasnovsky,Ingvar Bjarnason,Savvas Papagrigoriadis
DOI: https://doi.org/10.1111/codi.13046
IF: 3.4
2015-10-01
Colorectal Disease
Abstract:Our understanding of the human microbiome and host–microbiome interactions is rapidly evolving, with increasing recognition that bacteria play an important and beneficial role in health. Probiotics can modulate the gut microbiome, providing a beneficial health effect, but research is at a nascent stage. The purpose of this study was to review the evidence currently available, to help clinicians and patients make informed decisions. Probiotics are regulated as food supplements, not medications, across Europe and the USA [1,2]. The European Food Safety Authority has rejected over 260 applications on the health benefits of probiotics (accepting none), and the United States Food and Drug Administration has also not approved a single probiotic for reducing the risk of disease [3,4]. Regardless, probiotics continue to be marketed to the general public with little scientific oversight, resulting in a European market of € 1.4 billion [5].
What problem does this paper attempt to address?